Appointments

Mogrify has announced the appointment of Dr Jonathan Appleby as chief scientific officer.

Dr Appleby, with his extensive experience, is set to spearhead the Company's therapeutic programmes, as a promising future for Mogrify awaits.

Renowned scientist Dr Darrin M Disley OBE, CEO at Mogrify, reported: “We are thrilled to welcome Jon to the Mogrify Executive Team. Following a comprehensive global search that considered experienced medicine makers from across the cell and gene therapy paradigm, Jon’s particular expertise in advancing innovative and first-in-class medicines for patients with limited treatment options makes him the ideal candidate for leading Mogrify’s pipeline of novel in vivo reprogramming therapies through preclinical translation and into first in-human studies.”

Dr Appleby comes to Mogrify from the Cell and Gene Therapy Catapult, where he oversaw the R&D team for five years, focusing on ATMP manufacturing procedures and analytical development, while serving as executive director and chief scientific officer. His broad resume, which includes leadership positions in the ARSA gene therapy team, CSO for Cell and Gene Therapy in GSK's Rare Diseases Unit, director and portfolio manager at the GSK Centre of Excellence for External Drug Development, where he discovered, inlicensed and developed new technologies and assets across a broad range of therapeutic areas, suggests that success in his new role is inevitable.

Dr Appleby is set to oversee the company's therapeutic programme advancement toward and into clinical development in the fields of ophthalmology, diabetes and otology.